Procoagulant

In ex-vivo human studies using non-anticoagulated blood TT-103MH is able to reduce blood coagulation time in healthy subjects and Haemophilic patients up to 95% (4.5 ± 0.5 minutes to 0.2 ± 0.03 minutes) and 90% (18 ± 1.2 minutes to 1.8 ± 0.3 minutes), respectively. The same potent procoagulant effects were observed in heparinized plasmas and from patients with coagulation factor deficiencies (Factor V, VII, VIII, IX, X, XI, and XII). 

New biotech drug for deep vein thrombosis symptoms. TT-105 is a monoclonal antibody that shows high potency, good selectivity and demonstrates high efficacy in ex-vivo human experiments and in several in vivo animal models.

Know the novel TT-103MH, the haemostatic drug by Thrombotargets. It is a new way for treating topically all kinds of bleeding. See here the characteristics of this revolutionary haemostatic drug.

Know the TT-103MH by Thrombotargets. The antihemorrhagic drug that Thrombotargets' team is developing for bleeding treatments. Revolutionary topical administration. Know the characteristic of this antihemorrhagic drug.